US Bancorp
OPRX icon

US Bancorp’s OptimizeRx OPRX Stock Holding History

US Bancorp’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21
Closed -$431 – 4164
2025
Q3 		$431 Buy
+21
New +$333 ﹤0.01% 3881
2024
Q4 		– Sell
-1,325
Closed -$10.2K – 4240
2024
Q3 		$10.2K Buy
1,325
+1,021
+336% +$9.07K ﹤0.01% 3360
2024
Q2 		$3.04K Hold
304
– – ﹤0.01% 3630
2024
Q1 		$3.69K Buy
+304
New +$4.41K ﹤0.01% 3596
2023
Q4 		– Sell
-48
Closed -$373 – 4097
2023
Q3 		$373 Hold
48
– – ﹤0.01% 3883
2023
Q2 		$686 Hold
48
– – ﹤0.01% 3850
2023
Q1 		$702 Sell
48
-342
-88% -$5.72K ﹤0.01% 3917
2022
Q4 		$6.55K Buy
390
+342
+713% +$5.91K ﹤0.01% 3428
2022
Q3 		$1K Sell
48
-517
-92% -$10.2K ﹤0.01% 3988
2022
Q2 		$16K Buy
565
+469
+489% +$13.9K ﹤0.01% 3183
2022
Q1 		$4K Buy
96
+50
+109% +$2.21K ﹤0.01% 3680
2021
Q4 		$3K Buy
+46
New +$3.49K ﹤0.01% 3816
2021
Q3 		– Sell
-64
Closed -$4K – 4155
2021
Q2 		$4K Buy
+64
New +$3.26K ﹤0.01% 3671

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's OPRX Position: Q4 2025 in Review

US Bancorp sold out of OptimizeRx (OPRX) in Q4 2025, closing a stake of 21 shares — an estimated $431 sold.

US Bancorp first reported a position in OPRX in Q2 2021 and held it in 13 quarters. The position peaked at $16K in Q2 2022. 129 funds tracked by Wall St. Rank hold OPRX as of Q4 2025.

  • US Bancorp reported no remaining OptimizeRx position as of Q4 2025 after selling out during the quarter.
  • US Bancorp sold 21 OptimizeRx shares in Q4 2025, an estimated $431.
  • US Bancorp first reported a position in OptimizeRx in Q2 2021 and held it in 13 quarters.
  • US Bancorp's OptimizeRx position peaked at $16K in Q2 2022.
  • 129 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2025.

Based on US Bancorp's 13F filing for Q4 2025, filed 30 Jan 2026.